
[Cancer Research 60, 288-292, January 15, 2000]
© 2000 American Association for Cancer Research
Nuclear Matrix Proteins Associated with DNA in Situ in Hormone-dependent and Hormone-independent Human Breast Cancer Cell Lines1
Virginia A. Spencer,
Shanti K. Samuel and
James R. Davie2
Manitoba Institute of Cell Biology and the Department of Biochemistry and Molecular Biology, University of Manitoba, Winnipeg, Manitoba R3E 0V9, Canada
 |
ABSTRACT
|
|---|
The nuclear matrix is a dynamic RNA-protein complex that organizes
chromatin and regulates nuclear DNA metabolism. Nuclear matrix proteins
informative in the diagnosis of cancer have been identified. Here, the
nuclear matrix breast cancer proteins (NMBCs) cross-linked to nuclear
DNA in situ with cisplatin in human breast cancer cell
lines were analyzed by two-dimensional gel electrophoresis. We
identified NMBCs that were differentially associated with nuclear DNA
of hormone-dependent and -independent breast cancer cell lines. Three
DNA cross-linked NMBCs were found to be exclusive to estrogen
receptor-positive, hormone-dependent breast cancer cells, whereas two
NMBCs were observed only in estrogen receptor-negative,
hormone-independent breast cancer cells. Changes in these NMBCs were
observed when hormone-dependent breast cancer cells became hormone
independent. Furthermore, we show that the intermediate filament
protein vimentin is associated with the nuclear DNA of MDA-MB-231
breast cancer cells, an estrogen receptor-negative, hormone-independent
breast cancer cell line with high metastatic potential. These nuclear
matrix DNA-binding proteins may play important roles in breast
tumorigenesis.
 |
INTRODUCTION
|
|---|
Nuclear DNA is organized into loop domains through interactions
between MARs3
(DNA sequences at the base of the loop) and nuclear matrix proteins,
such as lamins, SatB1, SAF-B/HET, and ARBP (1
, 2)
.
Aberrant expression of nuclear matrix, MAR-binding proteins could
result in the reorganization of chromatin in cancer cells
(3)
.
The nuclear matrix is a component of the tissue matrix system, which
also consists of the cytoskeleton and extracellular matrix. The
interplay between these dynamic networks affects nuclear structure,
gene expression, and cell phenotype (4, 5, 6, 7)
. Using the
cross-linker cis-diamminedichloroplatinum (II) (cisplatin),
we found that cytokeratins, which are intermediate filament
proteins, are associated with nuclear DNA in breast cancer cells. In
ER-positive, hormone-dependent breast cancer cells, the interaction
between cytokeratins and DNA was modulated by estrogens; however, in
ER+, hormone-independent breast cancer cells, this interaction was no
longer regulated by estrogens (8)
. Thus, both nuclear
matrix proteins and intermediate filament proteins appear to have roles
in the organization of nuclear DNA.
In addition to serving a role in the organization of chromatin, the
nuclear matrix provides a platform for the assembly of protein machines
(e.g., replication and transcription factories) involved in
the processing of the genetic information (9
, 10)
.
Proteins and enzymes involved in transcription, chromatin modification,
replication, and RNA splicing are targeted to specific nuclear sites,
and the nuclear matrix targeting sequences of transcription factors
have been identified (11, 12, 13, 14, 15)
.
The organization and composition of the nuclear matrix is dynamic,
changing with nuclear activity (16, 17, 18)
. Some nuclear
matrix proteins are found in most cell types (e.g.,
heterogeneous ribonuclear proteins), whereas others are cell-,
differentiation-, or tumor-specific (19
, 20)
. The latter
group of nuclear matrix proteins can distinguish a malignant cell from
a benign or normal cell. Thus, the identification of these nuclear
matrix biomarkers has potential in the diagnosis and prognosis of
cancer (21)
. In an analysis of nuclear matrix proteins
from human breast cancer cell lines, we identified nuclear matrix
proteins that were found in either well-differentiated or poorly
differentiated human breast cancer cells (22)
.
In this study, we used in situ cross-linking by cisplatin to
identify nuclear proteins that were differentially associated with
nuclear DNA in hormone-dependent and -independent human breast cancer
cells. Analyses of two-dimensional gel patterns of proteins
cross-linked to nuclear DNA revealed that many of the proteins
cross-linked to DNA in situ with cisplatin were common to
hormone-dependent and hormone-independent cell lines. However, proteins
differentially cross-linked to nuclear DNA in these two groups of cell
lines were identified. Parallel analysis of two-dimensional gel
patterns of nuclear matrix proteins isolated from the cell lines showed
that the most proteins differentially cross-linked to DNA were nuclear
matrix proteins.
 |
MATERIALS AND METHODS
|
|---|
Cell Culture.
ER+, hormone-dependent (MCF-7, T-47D, T-47D5, and ZR-75), ER+,
hormone-independent (T5-PRF), and ER-, hormone-independent
(MDA-MB-231, MDA-MB-468, and BT-20) human breast cancer cell lines were
used in this study. MCF-10A1, an ER-, hormone-independent,
spontaneously immortalized breast epithelial cell line developed from a
reduction mammoplasty breast tissue sample was used as a control.
Culturing conditions for the cell lines were as described previously
(22)
.
Isolation and Analysis of Nuclear Matrix Proteins and Proteins
Cross-linked to DNA in Situ.
Nuclear matrices were isolated from the breast cancer cell lines
as described previously (22)
. Intermediate filament
proteins were removed from the nuclear matrix protein preparation
(23)
. Analysis of the nuclear matrix proteins of each cell
line was done at least three times. DNA-protein cross-linking was
performed as described previously (8)
. Briefly, MCF-7
cells at a density of 1 x 106
cells/ml were resuspended in Hanks buffer containing sodium acetate
instead of NaCl at the same concentration. The cells were incubated
with 1 mM cisplatin at 37°C for 2 h with gentle
shaking. Following this incubation, cells were treated with lysis
buffer (5 M urea, 2 M guanidine-HCl, 2
M NaCl, and 0.2 M potassium phosphate, pH 7.5).
Hydroxylapatite (4 g/20 A260 units of
lysate, Bio-Rad, Richmond, CA) was then added. The hydroxylapatite
resin was washed with lysis buffer to remove RNA and proteins not
cross-linked to DNA. To reverse the cross-linking, the hydroxylapatite
was incubated in lysis buffer containing 1 M
thiourea instead of 5 M urea. By doing so, the
proteins were released from hydroxylapatite, while the DNA remained
bound. Three separate cross-linking experiments were performed for each
cell line studied on cells grown from three consecutive passages. Only
proteins that consistently appeared in all three cross-linked profiles
of a cell line were considered representative DNA-binding proteins.
Two-dimensional PAGE was performed as described previously
(24)
. Gels were stained with silver using the Amersham
Pharmacia Biotech Plus One Silver Staining Kit, Protein
and then dried between sheets of gel drying film (Promega Corp.) at
room temperature. Stained gels were scanned using a PDI 325OE
densitometer (PDI, Huntington Station, NY), and the data were analyzed
with Image Master software (Amersham Pharmacia Biotech).
Immunoblot Analyses.
Proteins electrophoresed on SDS-polyacrylamide gels were transferred to
nitrocellulose (Bio-Rad) as described previously (25)
. The
nitrocellulose membranes were then immunochemically stained with
anti-vimentin antibodies, followed by goat anti-rabbit antibodies
(Bio-Rad) conjugated to horseradish peroxidase. The immunochemical
staining was detected using enhanced chemiluminescence detection system
(Amersham Pharmacia Biotech).
 |
RESULTS
|
|---|
ER+, hormone-dependent (T-47D, MCF-7, and ZR-75), ER+,
hormone-independent (T5-PRF), and ER-, hormone-independent breast
cancer cell lines and an ER-, hormone-independent, spontaneously
immortalized, nontumorigenic human breast epithelial cell line
(MCF-10A1) were incubated with cisplatin. Proteins cross-linked to
nuclear DNA were isolated and analyzed by two-dimensional gel
electrophoresis. Representative silver-stained two-dimensional gel
patterns of proteins cross-linked to DNA of the various cell lines are
shown in Figs. 1
and 2
(see Fig. 3
for a schematic of the two-dimensional gel pattern data). To compare
the proteins in the various gel patterns, several exogenous proteins
were used to align protein patterns. Carbamylated carbonic anhydrase
(30 kDa, pI 4.86.7) served as a reference for determining the
molecular mass and isoelectric point of the proteins. Two-dimensional
SDS-PAGE standards were used to determine the molecular mass of the
proteins.

View larger version (106K):
[in this window]
[in a new window]
[Download PPT slide]
|
Fig. 1. Proteins cross-linked to DNA by cisplatin in
situ from ER+ hormone-dependent and -independent breast cancer
cell lines. Eighty µg of DNA cross-linked proteins from cells treated
with 1 mM cisplatin were electrophoretically resolved on
two-dimensional gels. The gels were stained with silver.
ca, position of the carbamylated forms of carbonic
anhydrase. The position of the molecular mass standards (kDa) is shown
to the left of the two-dimensional gel patterns.
LA and LC, lamin A and C, respectively.
cK8, cK18, and cK19, cytokeratins 8, 18,
and 19, respectively. hK, transcription factor hnRNPK.
R1 and R2, which are two proteins found
cross-linked to nuclear DNA in all cell types tested, serve as internal
reference markers.
|
|

View larger version (127K):
[in this window]
[in a new window]
[Download PPT slide]
|
Fig. 2. Proteins cross-linked to DNA by cisplatin in
situ from ER-, pseudonormal breast epithelial cell line and
hormone-independent breast cancer cell lines. Eighty µg of proteins
cross-linked to DNA with 1 mM cisplatin were
electrophoretically resolved on two-dimensional gels. The gels were
stained with silver. The position of the molecular mass standards (kDa)
is shown to the left of the two-dimensional gel
patterns. For definitions of ca, LA, LC, hK, cK8, cK18, cK19,
R1, and R2 see legend to Fig. 1
.
BN, proteins cross-linked to DNA in pseudonormal but not
cancer cells. V, vimentin.
|
|

View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Fig. 3. A schematic representation of the two-dimensional gel
pattern data of proteins cross-linked to nuclear DNA by cisplatin in
pseudonormal breast epithelial and breast cancer cell lines. The
position of the molecular mass standards (kDa) is shown to the
left of the two-dimensional gel patterns. For
definitions of ca, LA, LC, hK, cK8, cK18, cK19, R1, R2,
and BN, see legends to Figs. 1
2
.
|
|
The gel patterns of proteins isolated from the various cell lines were
similar, providing evidence that many of these proteins cross-linked to
DNA were in common. A comparison of the isoelectric point and molecular
mass co-ordinates of the common DNA-cross-linked proteins with
the co-ordinates of proteins identified in previous studies showed that
the transcription factor hnRNPK (60 kDa; pI 5.25.4) was cross-linked
to DNA in all cell lines studied. Two proteins (labeled R1
and R2 in the figures) were consistently observed in
the gel patterns. Lamins A and C were also seen in the gel patterns
when higher loads of protein were used. In addition, cytokeratins 8 (54
kDa, pI 5.4), 18 (45 kDa, pI 5.3), and 19 (41 kDa, pI 4.9) were
identified in the various two-dimensional gel patterns.
Despite the large degree of similarity in the gel patterns of proteins
cross-linked to DNA, differences in the abundance of proteins in the
two-dimensional gel patterns of proteins isolated from pseudonormal
breast epithelial, hormone-dependent, and hormone-independent breast
cancer cell lines were observed. In comparing protein levels, hnRNPK
was used as an internal loading control. The relative abundance of this
protein appeared to be similar in the gel patterns. Table 1
details the proteins displaying differences in silver staining
intensity of at least 5-fold. The molecular mass and isoelectric point
values of these proteins are summarized in Table 1
. Three
DNA-cross-linked proteins were detected only in the pseudonormal
MCF-10A1 breast epithelial cell line (BN1, BN2, and BN3), whereas three
proteins (NMBC7, NMBC8, and NMBC9) were present at significantly higher
levels in the hormone-dependent cell lines MCF-7, T-47D, and T-47D5
when compared to levels observed in other cell line preparations.
Hormone-independent, ER- human breast cancer cell lines also displayed
two DNA-cross-linked proteins (NMBC10 and NMBC11) that were present at
undetectable levels in hormone-dependent or pseudonormal breast
epithelial cell lines.
View this table:
[in this window]
[in a new window]
|
Table 1 Proteins found in pseudo-normal breast epithelial and breast cancer
cell lines
Proteins cross-linked to nuclear DNA of pseudonormal breast epithelial
cells but absent in breast cancer cells are labeled as BN. Proteins
cross-linked to nuclear DNA of breast cancer cells but not to nuclear
DNA of pseudonormal breast epithelial cells are labeled NMBC. The
absence or presence of a protein and the level of the protein among the
proteins cross-linked to nuclear DNA or associated with the nuclear
matrix are indicated by -, +, and ++.
|
|
The DNA-cross-linked proteins isolated from the ER+,
hormone-independent, T5-PRF breast cancer cell line were compared to
those of the parent cell line (T-47D5; ER+, hormone-dependent) from
which the hormone-independent cell line was obtained. The
two-dimensional gel pattern of DNA-cross-linked proteins isolated from
T-47D5 cells was similar to that of the MCF-7 DNA-cross-linked proteins
with the exception that lamins A and C were much more prominent in the
T-47D5 protein pattern (data not shown). As with the MCF-7 protein
pattern, DNA-cross-linked proteins NMBC7, NMBC8, and NMBC9 from T-47D5
cells were at greater levels than those of pseudonormal (MFC-10A1) and
ER- cell lines. In contrast, the levels of these three
DNA-cross-linked proteins were considerably reduced in the T5-PRF cell
line (Table 1)
.
To determine whether the DNA-cross-linked proteins listed in Table 1
were nuclear matrix proteins, we inspected the two-dimensional gel
pattern of nuclear matrix proteins from the respective cell line for
the presence of the DNA-cross-linked protein (22)
. This
comparison showed that all but two (BN1 and BN2) of these
DNA-cross-linked proteins were nuclear matrix proteins (Table 1)
.
However, these DNA-cross-linked proteins appeared to be present at
similar levels in the various nuclear matrix protein preparations in
which the intermediate filament proteins had been removed (data not
shown).
In a previous study, five nuclear matrix proteins, designated
NMBC1NMBC5, were found to be more abundant in well-differentiated
cell lines (T-47D, MCF-7, ZR-75, and T5-PRF), whereas NMBC6 was present
at higher levels in poorly differentiated breast cancer cell lines
(22)
. Among the DNA-cross-linked proteins, NMBC1 (57 kDa,
pI 5.5) and NMBC2 (62 kDa, pI 5.1) were the most prominent in all of
the cell lines studied, including MCF-10A1. NMBC3 (40 kDa, pI 5.4),
NMBC4 (41 kDa, pI 5.3), NMBC5 (39 kDa, pI 5.5), and NMBC6 (52 kDa, pI
5.7) were not detected in the two-dimensional profiles of
DNA-cross-linked proteins.
Previously, we had found that the intermediate filament proteins
cytokeratins 8, 18, and 19 of human breast cancer cell lines were
cross-linked to nuclear DNA by cisplatin (8)
. Among these
cell lines, MDA-MB-231 cells also express the intermediate filament
protein vimentin. The MDA-MB-231 preparation had a protein with a
molecular mass and pI (57 kDa, pI 5.0) similar to that of vimentin. To
provide evidence that vimentin was cross-linked to nuclear DNA in
situ, the proteins were analyzed by immunoblotting with
anti-vimentin antibodies. For comparison, a preparation of high-salt
Triton-insoluble proteins enriched in cytoskeletal proteins was
included in the analysis. Fig. 4
shows that vimentin was cross-linked to nuclear DNA in situ
in MDA-MB-231 cells with cisplatin. As a control, proteins cross-linked
to DNA of MDA-MB-468 cells, which do not express vimentin, were also
analyzed by immunoblotting with anti-vimentin antibodies.
Immunoreactive protein was not detected in this sample, showing that
the antibody was specific for vimentin (data not shown).

View larger version (52K):
[in this window]
[in a new window]
[Download PPT slide]
|
Fig. 4. Association of vimentin with nuclear DNA of a metastatic
ER- human breast cancer cell line. Cisplatin DNA-cross-linked
(X-LINK) proteins (45 µg) and cellular intermediate
filament (IF) proteins (45 µg) from the
MDA-MB-231 cell line were resolved on a one-dimensional SDS
polyacrylamide gel, transferred to a nitrocellulose membrane, and
immunochemically stained with anti-vimentin antibody. Lane
1, cellular intermediate filaments. Lane 2,
cisplatin DNA-cross-linked proteins. V, vimentin. This
is a representative result obtained from three different
preparations.
|
|
 |
DISCUSSION
|
|---|
The nuclear matrix is involved in the organization and function of
nuclear DNA (18
, 26
, 27)
. Nuclear matrix proteins that are
informative in cancer diagnosis have been identified (21
, 28 , 29)
. Previously, we identified nuclear matrix proteins, which
were informative in breast cancer (22)
. Here, a strategy
to identify nuclear matrix proteins that are associated with nuclear
DNA in situ was applied to compare pseudonormal breast
epithelial with breast cancer cell lines. The nuclear matrix proteins
bound to nuclear DNA presumably have a function in chromatin
organization and/or function. Thus, the nuclear matrix proteins
differentially associated with nuclear DNA in cancer versus
normal cells may have a role in chromosome instability, as well as in
aberrant nuclear DNA arrangement and/or metabolism in cancer (3
, 30)
.
The cross-linker used in this study was cisplatin. This agent is
particularly useful in the identification of nuclear matrix proteins
involved in the organization of nuclear DNA because it preferentially
cross-links nuclear matrix proteins to MAR DNA (23)
.
Unlike formaldehyde, which will cross-link protein to DNA and protein
to protein, cisplatin directly cross-links DNA to protein (cross-link
distance, 4 Å; Ref. 31
).
We identified several NMBC proteins that are differentially
associated with nuclear DNA of ER+, hormone-dependent versus
ER-, hormone-independent breast cancer cells. As the features of
breast cancer cells are similar to that of their corresponding tumors,
the NMBCs identified in this study (e.g., NMBC10 and NMBC11)
may serve to distinguish breast cancer epithelial cell types present in
breast tumors (32
, 33)
. The identification of nuclear
matrix proteins differentially associated with the chromatin of T5-PRF
(ER+, hormone-independent cell line) and parent T-47D5 (ER+,
hormone-dependent cell line) is of particular importance in breast
cancer progression because most ER+ tumors will eventually become
hormone independent (34)
. It should be noted that although
the T5-PRF cell line was hormone independent, the cells did not
assume the phenotype of a ER-, hormone-independent cell line with
regards to association of NMBC10 and NMBC11 with nuclear DNA.
We have discussed previously that the conventional method of
isolating and identifying cancer-specific nuclear matrix proteins may
miss informative nuclear matrix proteins (8)
. During the
preparation of nuclear matrix proteins, intermediate filaments are
often removed (24)
. Previously, we reported that
intermediate filament proteins, cytokeratins, were bound to nuclear DNA
of breast cancer cells. Here, we show for the first time that vimentin
is in contact with nuclear DNA in the MDA-MB-231 cell line, an ER-
human breast cancer cell line with high metastatic potential. An
in vitro study by Wang et al.
(35)
has shown that vimentin binds in a sequence-specific
manner to DNA. Vimentin contributes to the metastatic potential of
human breast tumors and melanoma (36, 37, 38)
. It is
conceivable that intermediate filaments composed of vimentin
communicate signals from the extracellular matrix to nuclear DNA,
resulting in changes in gene expression associated with metastasis
(5
, 39)
.
In summary, the characterization of nuclear matrix proteins and
proteins cross-linked to DNA by cisplatin in situ are two
complementary approaches that can be used to identify informative
nuclear matrix proteins in cancer diagnosis.
 |
FOOTNOTES
|
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This research was supported by Medical Research
Council of Canada Grant RO-15183 and by the Manitoba Health Research
Council. J. R. D. is a Medical Research Council of Canada Senior
Scientist. 
2 To whom requests for reprints should be
addressed, at Manitoba Institute of Cell Biology, University of
Manitoba, 100 Olivia Street, Winnipeg, Manitoba R3E OV9, Canada.
Phone: (204) 787-2391; Fax: (204) 787-2190; E-mail: Davie{at}cc.umanitoba.ca 
3 The abbreviations used are: MAR, matrix
attachment region; NMBC, nuclear matrix breast cancer protein;
ER, estrogen receptor. 
Received 7/15/99.
Accepted 11/11/99.
 |
REFERENCES
|
|---|
-
Bode J., Stengert-Iber M., Kay V., Schlake T., Dietz-Pfeilstetter A. Scaffold/matrix-attached regions: topological switches with multiple regulatory functions. Crit. Rev. Eukaryotic Gene Expression, 6: 115-138, 1996.[Medline]
-
Pemov A., Bavykin S., Hamlin J. L. Attachment to the nuclear matrix mediates specific alterations in chromatin structure. Proc. Natl. Acad. Sci. USA, 95: 14757-14762, 1998.[Abstract/Free Full Text]
-
Yanagisawa J., Ando J., Nakayama J., Kohwi Y., Kohwi-Shigematsu T. A matrix attachment region (MAR)-binding activity due to a p114 kilodalton protein is found only in human breast carcinomas and not in normal and benign breast disease tissues. Cancer Res., 56: 457-462, 1996.[Abstract/Free Full Text]
-
Penman S. Rethinking cell structure. Proc. Natl. Acad. Sci. USA, 92: 5251-5257, 1995.[Abstract/Free Full Text]
-
Lelièvre S. A., Weaver V. M., Nickerson J. A., Larabell C. A., Bhaumik A., Petersen O. W., Bissell M. J. Tissue phenotype depends on reciprocal interactions between the extracellular matrix and the structural organization of the nucleus. Proc. Natl. Acad. Sci. USA, 95: 14711-14716, 1998.[Abstract/Free Full Text]
-
Ingber D. In search of cellular control: signal transduction in context. J. Cell Biochem. Suppl., 3031: 232-237, 1998.
-
Cervoni L., Ferraro A., Eufemi M., Altieri F., Chichiarelli S., Turano C. Cross-linked telomere-protein complexes from chicken erythrocyte nuclei: isolation by a new procedure. Biochem. Biophys. Res. Commun., 254: 517-521, 1999.[Medline]
-
Spencer V. A., Coutts A. S., Samuel S. K., Murphy L. C., Davie J. R. Estrogen regulates the association of intermediate filament proteins with nuclear DNA in human breast cancer cells. J. Biol. Chem., 273: 29093-29097, 1998.[Abstract/Free Full Text]
-
Misteli T., Spector D. L. The cellular organization of gene expression. Curr. Opin. Cell Biol., 10: 323-331, 1998.[Medline]
-
Schul W., de Jong L., van Driel R. Nuclear neighbours: the spatial and functional organization of genes and nuclear domains. J. Cell Biochem., 70: 159-171, 1998.[Medline]
-
Stenoien D., Sharp Z. D., Smith C. L., Mancini M. A. Functional subnuclear partitioning of transcription factors. J. Cell Biochem., 70: 213-221, 1998.[Medline]
-
McNeil S., Gou B., Stein J. L., Lian J. B., Bushmeyer S., Seto E., Atchison M. L., Penman S., van Wijnen A. J., Stein G. S. Targeting of the YY1 transcription factor to the nucleolus and the nuclear matrix in situ: the C-terminus is a principal determinant for nuclear trafficking. J. Cell. Biochem., 68: 500-510, 1998.[Medline]
-
Zeng C., McNeil S., Pockwinse S., Nickerson J., Shopland L., Lawrence J. B., Penman S., Hiebert S., Lian J. B., van Wijnen A. J., Stein J. L., Stein G. S. Intranuclear targeting of AML/CBF
regulatory factors to nuclear matrix-associated transcriptional domains. Proc. Natl. Acad. Sci. USA, 95: 1585-1589, 1998.[Abstract/Free Full Text]
-
Hendzel M. J., Kruhlak M. J., Bazett-Jones D. P. Organization of highly acetylated chromatin around sites of heterogeneous nuclear RNA accumulation. Mol. Biol. Cell, 9: 2491-2507, 1998.[Abstract/Free Full Text]
-
Berezney R., Wei X. The new paradigm: integrating genomic function and nuclear architecture. J. Cell Biochem. Suppl., 3031: 238-242, 1998.
-
Chen H. Y., Sun J.-M., Hendzel M. J., Rattner J. B., Davie J. R. Changes in the nuclear matrix of chicken erythrocytes that accompany maturation. Biochem. J., 320: 257-265, 1996.
-
Holth L. T., Chadee D. N., Spencer V. A., Samuel S. K., Safneck J. R., Davie J. R. Chromatin, nuclear matrix and the cytoskeleton: role of cell structure in neoplastic transformation. Int. J. Oncol., 13: 827-837, 1998.[Medline]
-
Nickerson J. A. Nuclear dreams: the malignant alteration of nuclear architecture. J. Cell Biochem., 70: 172-180, 1998.[Medline]
-
Gerner C., Holzmann K., Grimm R., Sauermann G. Similarity between nuclear matrix proteins of various cells revealed by an improved isolation method. J. Cell Biochem., 71: 363-374, 1998.[Medline]
-
Replogle-Schwab T. S., Pienta K. J., Getzenberg R. H. The utilization of nuclear matrix proteins for cancer diagnosis. Crit. Rev. Eukaryotic Gene Expression, 6: 103-113, 1996.[Medline]
-
Hughes J. H., Cohen M. B. Nuclear matrix proteins and their potential applications to diagnostic pathology. Am. J. Clin. Pathol., 111: 267-274, 1999.[Medline]
-
Samuel S. K., Minish M. M., Davie J. R. Nuclear matrix proteins in well and poorly differentiated human breast cancer cell lines. J. Cell. Biochem., 66: 9-15, 1997.[Medline]
-
Davie J. R., Samuel S., Spencer V., Bajno L., Sun J.-M., Chen H. Y., Holth L. T. Nuclear matrix: application to diagnosis of cancer and role in transcription and modulation of chromatin structure. Gene Ther. Mol. Biol., 1: 509-528, 1998.
-
Samuel S. K., Minish T. M., Davie J. R. Altered nuclear matrix protein profiles in oncogene transformed fibroblasts exhibiting high metastatic potential. Cancer Res., 57: 147-151, 1997.[Abstract/Free Full Text]
-
Samuel S. K., Spencer V. A., Bajno L., Sun J.-M., Holth L. T., Oesterreich S., Davie J. R. In situ cross-linking by cisplatin of nuclear matrix-bound transcription factors to nuclear DNA of human breast cancer cells. Cancer Res., 58: 3004-3008, 1998.[Abstract/Free Full Text]
-
de Belle I., Cai S., Kohwi-Shigematsu T. The genomic sequences bound to special AT-rich sequence-binding protein 1 (SATB1) in vivo in Jurkat T cells are tightly associated with the nuclear matrix at the bases of the chromatin loops. J. Cell Biol., 141: 335-348, 1998.[Abstract/Free Full Text]
-
Hendzel M. J., Boisvert F., Bazett-Jones D. P. Direct visualization of a protein nuclear architecture. Mol. Biol. Cell, 10: 2051-2062, 1999.[Abstract/Free Full Text]
-
Subong E. N., Shue M. J., Epstein J. I., Briggman J. V., Chan P. K., Partin A. W. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO: 4- 216) recognizes nucleophosmin/B23. Prostate, 39: 298-304, 1999.[Medline]
-
Zippe C., Pandrangi L., Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J. Urol., 161: 62-65, 1999.[Medline]
-
Pienta K. J., Ward W. S. An unstable nuclear matrix may contribute to genetic instability. Med. Hypotheses, 42: 45-52, 1994.[Medline]
-
Olinski R., Wedrychowski A., Schmidt W. N., Briggs R. C., Hnilica L. S. In vivo DNA-protein cross-linking by cis- and trans- diamminedichloroplatinum(II). Cancer Res., 47: 201-205, 1987.[Abstract/Free Full Text]
-
Robertson J. F. R. Oestrogen receptor: A stable phenotype in breast cancer. Br. J. Cancer, 73: 5-12, 1996.[Medline]
-
Wistuba I. I., Behrens C., Milchgrub S., Syed S., Ahmadian M., Virmani A. K., Kurvari V., Cunningham T. H., Ashfaq R., Minna J. D., Gazdar A. F. Comparison of features of human breast cancer cell lines and their corresponding tumors. Clin. Cancer Res., 4: 2931-2938, 1998.[Abstract]
-
Murphy L. C. Mechanisms of hormone independence in human breast cancer. In Vivo, 12: 95-106, 1998.[Medline]
-
Wang X., Tolstonog G., Shoeman R. L., Traub P. Selective binding of specific mouse genomic DNA fragments by mouse vimentin filaments in vitro. DNA Cell Biol., 15: 209-225, 1996.[Medline]
-
Hendrix M. J., Seftor E. A., Seftor R. E., Trevor K. T. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am. J. Pathol., 150: 483-495, 1997.[Abstract]
-
Domagala W., Markiewski M., Harezga B., Dukowicz A., Osborn M. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin. Cancer Res., 2: 147-154, 1996.[Abstract/Free Full Text]
-
Chu Y. W., Seftor E. A., Romer L. H., Hendrix M. J. Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am. J. Pathol., 148: 63-69, 1996.[Abstract]
-
Hartig R., Shoeman R. L., Janetzko A., Tolstonog G., Traub P. DNA-mediated transport of the intermediate filament protein vimentin into the nucleus of cultured cells. J. Cell Sci., 111: 3573-3584, 1998.[Abstract]
This article has been cited by other articles:

|
 |

|
 |
 
J.-M. Sun, H. Y. Chen, and J. R. Davie
Differential Distribution of Unmodified and Phosphorylated Histone Deacetylase 2 in Chromatin
J. Biol. Chem.,
November 9, 2007;
282(45):
33227 - 33236.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. He and J. R. Davie
Sp1 and Sp3 foci distribution throughout mitosis
J. Cell Sci.,
March 15, 2006;
119(6):
1063 - 1070.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. He, J.-M. Sun, L. Li, and J. R. Davie
Differential Intranuclear Organization of Transcription Factors Sp1 and Sp3
Mol. Biol. Cell,
September 1, 2005;
16(9):
4073 - 4083.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Thomas, C. A. Messam, B. A. Spengler, J. L. Biedler, and R. A. Ross
Nestin Is a Potential Mediator of Malignancy in Human Neuroblastoma Cells
J. Biol. Chem.,
July 2, 2004;
279(27):
27994 - 27999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. A. Spencer, S. K. Samuel, and J. R. Davie
Altered Profiles in Nuclear Matrix Proteins Associated with DNA in Situ during Progression of Breast Cancer Cells
Cancer Res.,
February 1, 2001;
61(4):
1362 - 1366.
[Abstract]
[Full Text]
|
 |
|